RGS
Director Trades
| Date | Director | Value |
|---|
Company News
Market wrap: risk assets sold as market loses ground for the week
The Easter hangover continued for the Australian share market on Friday, with the ASX 200 shedding 0.6% or 40.7 points to 7773.3 points as markets digested the news that US interest rates may not fall at all this year. That meant the ASX 200 had fallen 1.6% for the week, recording falls on three of […]
Regeneus and Cambium merge to refine dry eye treatment development
Australian regenerative medicine firm Regeneus (ASX: RGS) and US-headquartered Cambium Medical Technologies (CMT) have completed a merger that will see them combine to further develop a novel biologic treatment for dry eye disease. Regeneus is a Sydney-based company focused on the development of innovative biologics for ophthalmology and tissue repair applications. Cambium Medical is a […]
Regeneus signs agreement with Kyocera for licensing of Progenza knee osteoarthritis drug to Japanese market
Clinical-stage regenerative medicine company Regeneus (ASX: RGS) has signed a licence and collaboration agreement with Kyocera Corporation to develop and commercialise its lead stem cell platform technology Progenza for the treatment of knee osteoarthritis in the Japanese market. Under the terms of the agreement, Kyocera will fund the manufacturing, development, and commercialisation costs for the […]
Regeneus receives Chinese patent for biomarkers in monitoring disease progression for stem cell therapy
Regenerative medicine company Regeneus (ASX: RGS) has reached a significant milestone in its mission to market its proprietary biomarkers in China. The company is developing a portfolio of innovative cellular therapies targeting “significant unmet medical needs” and is currently progressing a licence-driven strategy to commercialise its product portfolio which already has in excess of 80 […]
Japanese patent office grants key patent for Regeneus’ Progenza stem cell technology
Regeneus (ASX: RGS) today announced that the Japanese patent office has issued a decision to grant a key patent covering the composition, manufacture and use of Progenza stem cell technology. Progenza is the company’s allogeneic off-the-shelf stem cell technology platform for the treatment of osteoarthritis and other inflammatory conditions for human and animal applications. Japanese […]